PURPOSE: To evaluate the effect of @entity1482 , a mineralocorticoid receptor antagonist, for nonresolving @entity989 . METHODS: This is a prospective, randomized, double-blinded, placebo-controlled crossover study. Sixteen eyes of 16 @entity1 with @entity989 and persistent @entity5173 ( @entity5173 ) for at least 3 months were enrolled. @entity1 were randomized to receive either @entity1482 50 mg or placebo once a day for 30 days, followed by a washout period of 1 week and then crossed over to either placebo or @entity1482 for another 30 days. The primary outcome measure was the changes from baseline in @entity5173 thickness at the apex of the @entity1713 . Secondary outcomes included subfoveal @entity3193 and the ETDRS best-corrected visual acuity. RESULTS: The mean duration of @entity989 before enrollment in study eyes was 10    16.9 months. Crossover data analysis showed a statistically significant reduction in @entity5173 in @entity1482 treated eyes as compared with the same eyes under placebo (P = 0.04). Secondary analysis on the first period (Day 0-Day 30) showed a significant reduction in subfoveal @entity2194 as compared with placebo (P = 0.02). No significant changes were observed in the best-corrected visual acuity. There were no complications related to treatment observed. CONCLUSION: In eyes with persistent @entity5173 due to @entity989 , @entity1482 significantly reduced both the @entity5173 and the subfoveal @entity3193 as compared with placebo.

XXXX FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2194 :: ('MESH:D005128', 'Disease') :: ['choroidal thickness in treated eyes'] @entity1713 :: ('MESH:D012163', 'Disease') :: ['serous retinal detachment'] @entity5173 :: ('MESH:D065634', 'Disease') :: ['SRF', 'subretinal fluid'] @entity3193 :: ('MESH:D015862', 'Disease') :: ['choroidal thickness'] @entity989 :: ('MESH:D012164', 'Disease') :: ['central serous chorioretinopathy'] @entity1482 :: ('MESH:D013148', 'Chemical') :: ['spironolactone']
@entity1482 :: (MESH:D013148,Chemical) :: ['SPIRONOLACTONE']
